Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Last Trade
$1.02
added more @1.02. While it is in this low range.
Shares of Halozyme Therapeutics, Inc. (NASDAQ: HALO) were trading higher by 0.62 percent during Thursday's afternoon.
Halozyme Therapeutics disclosed earlier in the day that AbbVie Inc (NYSE: ABBV) has dosed its first subject in a clinical trial evaluating the safety and pharmacokinetics of adalimumab with Halozyme's proprietary ENHANZE technology.
The initiation of the clinical study triggered an automatic $5 million milestone payment to Halozyme as part of a prior agreement established between the two companies.
"We are pleased that the first product candidate with AbbVie has been advanced into clinical testing just seven months after forming our collaboration agreement," said Dr. Helen Torley, president and chief executive officer. "The progress is encouraging as we seek to help an even broader population of patients with our ENHANZE platform."
Nice technical commentary on Market woes. Thanks
PPHM had 1 RS. I do not see the 1986 RS with TCLN as factor to consider.
Not always, but r/s is a loser's trick and shorts would have a field day if they pulled their 3rd reverse split.
Adding shares helps the bottom line. Nice share count.
the RSI in oversold territory. added more @.90
Not that I need anymore shares. Added more @.94
Thanks CP this all has been posted before. Hope more are understanding now. Thanks.
sulaco You made my morning read. Very insightful thoughts in all aspects of treatment. Thanks
sunstar excellent post as usual. Thanks EOM
Excellent CP, this is what a good post offers-good information.
BIO
Our investment in Bavi is good for the patient therefore good for our pocket book. Sunrise will begin the process.
RRDOG Appreciate your input. Lots of moving pieces culminating
together for patient and investor value.
Shareholders working in concert in posting valuable information
to assist us all in our investment in PPHM, Avid and Bavi is welcomed and useful. The rest well you all know. No need to read.
Good information Sunstar. Thanks. EOM
Hutschi- we now can say...
The MOA of Bavi with its efficacy should not only increase eligibility of patients for treatment but improve quality,lower side effects,help elicit a curative regimen combined with
Yervoy an anti-CTLA-4 antibody.
Important Safety Information for OPDIVO (nivolumab)and the OPDIVO+YERVOY Regimen
YERVOY® (ipilimumab) can cause serious side effects in many parts of your body which can lead to death. These serious side effects may include: intestinal problems (colitis) that can cause tears or holes (perforation) in the intestines; liver problems (hepatitis) that can lead to liver failure; skin problems that can lead to severe skin reaction; nerve problems that can lead to paralysis; hormone gland problems (especially the pituitary, adrenal, and thyroid glands); and eye problems.
These problems may happen anytime during treatment with YERVOY or after you have completed treatment. Your healthcare provider will check you for these problems during treatment with YERVOY. Your healthcare provider may treat you with corticosteroid medicines. Your healthcare provider should perform blood tests, such as liver, hormone, and thyroid function tests, before starting and during treatment with YERVOY. Your healthcare provider may need to delay or completely stop treatment with YERVOY if you have severe side effects.
BIO Yes the strategy is very clear but patients is wearing thin for some investors. The process takes time from lab to market on Bavi. We had a bump in the road back in 2012 but forging ahead now!
Create labeling strategies and implement new/revised labeling and support documentation for submissions.
• Possess a strong working knowledge of FDA regulations and guidance on ALP and apply understanding to business situations in the immuno-oncology field.
• Review labeling, advertising, promotional and other related materials for Peregrine's immuno-oncology products to ensure compliance with applicable FDA laws, regulations and guidance.
Archiek
Agree with your sentiment. Thanks
MH Bottom line. Clear strategy.
It's all pointing to the strategy of filing for Lung with Bavi/Doce closely followed by multiple filing for multiple indications through the various collaborations - should they produce the results we hope.
KRAK Prayed for you tonight. Hope all is well.
I am an independent investor you happens to believe Bavi will succeed. How about you?
BTW I am also believing it for the patients.
BINGO. Here is some of that analytic logic I was alluding to earlier.
Listen to you guys.... jeez, I hope your niece and nephews are not being fed this line of thinking.
IF desperation ever set in, Peregrine would have agreed to been bought out after Sept 2012
IF desperation ever set in, Peregrine would not have discovered sabotage
IF desperation ever set in lately.... Peregrine would have caved into a money deal with AstraZeneca and gave them exclusive rights for some cash just a few months ago
I am glad they did not become desperate and cave in... hell, another round of ROTH IRA tax free PPHM shares at these prices lasted till Jan 4th... : )
Bavi is building data points to expand labels into many indications through all of these collaborations not just for supporting data for SUNRISE trial to submit the BLA. If the process lends itself to what you describe below so be it. The results should put bavi at a very good leverage point upon approval. I for one expect approval on SUNRISE.
A sting in the eye to BMS as Peregrine nicely says no thank you and a sting in the eye to AZ as they had no leverage to secure an exclusive date with Peregrine and now a big sting in the eye to many at the partnering talks table as this collaboration just tells them all..... slowly but surely the truth will be told and this just may advance talks faster between Peregrine and others...
With any ability to analyze you are right.
Keep trying MSK, AZN & now NCCN says I'm right. Next
Agreed Krak whole heartedly. EOM
Great points made as usual eom
Two million dollar grant to National Comprehensive Cancer Network to help cancer patients not laughable but applaudable. More exposure etc. The PR states it well.
I will continue to pray for you sir as I have tonight.EOM
Nice post cheynew. EOM
His statement below speaks volumes about his confidence and determination of Bavi's moa.
Another statement from Dr Garnick three years ago that this is just a bump in the road.
Hell of a bump but who ever said that this was going to be easy!!!
Joan Massagué, PhD, a world leader in research on signaling pathways and transcriptional programs that regulate normal cell behavior and cancer metastasis, became Director of the Sloan Kettering Institute in 2014.
A native of Barcelona, Spain, Dr. Massagué earned his PhD in pharmacy and biochemistry from the University of Barcelona in 1978. In 1982, he completed a postdoctoral fellowship at Brown University, where he worked on mechanisms of insulin action. Later that year, he became assistant professor of biochemistry at the University of Massachusetts Medical School.
In 1989, Dr. Massagué joined Memorial Sloan Kettering as the Alfred P. Sloan Chair in Cancer Biology and was appointed a Howard Hughes Medical Institute investigator. He served as Chairman of the Sloan Kettering Institute Cell Biology Program from 1989 to 2003 and has been a Founding Chair of the Cancer Biology and Genetics Program since 2003. He is also a professor at Weill-Cornell Graduate School of Medical Sciences.
Throughout his 30-year career, Dr. Massagué has been lauded for the originality and importance of his work elucidating the mechanism of action for transforming growth factor-beta (TGF-ß) signaling. The TGF-ß family of proteins plays a key role in the proliferation and differentiation of many different cell types, controlling the formation and regeneration of tissues from embryonic life to adulthood.
Dr. Massagué identified the TGF-ß receptors, their mechanism of signal transduction, and the central concept of how this pathway controls cell division and developmental fate. He provided a direct explanation for how external signals block cell division through CDK inhibitors and cell fate through chromatin regulators. These mechanisms are crucial in embryonic development, and their disruption causes congenital disorders and cancer.
More recently, work led by Dr. Massagué has identified genes and mechanisms that promote cancer metastasis to the bone, lung, and brain in a number of cancer types. This research has illuminated the basis for cancer lethality and opened new avenues for treatment.
Dr. Massagué is a member of the US National Academy of Sciences, the Institute of Medicine, the American Academy of Arts and Sciences, the Spanish Royal Academies of Medicine and of Pharmacy, and the European Molecular Biology Organization. He is the recipient of many prestigious awards including the Passano Prize, the Vilcek Prize, the BBVA Frontiers of Science Prize, the Prince of Asturias Prize, the Pasarow Prize, and other honors.
NotBOB17 So sorry for the loss of your friend. I have lost my grand parents, uncle and mom to cancer. I joined this message board to team up with other folks to express views about research and get insights from others. My investments in BIO will help make a difference.This is my believe. Thankfully there are enough good folks to follow here.
VOL You mean like telling my manager about PPHM and the he goes and buys 60K shares the next day.
MH Bingo! This would be a very logical rational.
hutschi Thanks
I forwarded this link to my brother-in law since he is an individual investor of PPHM. He is a Marketing Director for a brokerage firm located about 25 miles outside San Diego. Perhaps he can attend.
The Function of Tumor Microenvironment in Cancer Progression
January 7 - 10, 2016
Hard Rock Hotel
San Diego, California, USA
http://www.aacr.org/Meetings/Pages/Program-Detail.aspx?EventItemID=73&DetailItemID=419&Day=01092016#.VoejSIqIXMI
Last year was generally a good investment year for me in biotech's.
Looking forward to some wins in my speculative portfolio. PPHM stands out as perhaps the best of those investment potentials with the Mechanism of Action being a combo treatment to improve SOC in many indications. GLTA for 2016.
BTW I greatly appreciate the input on this message board by many.
MH well articulated, this comes from an informed, confident and knowledgeable mind coupled with guarded confidence. Breath of fresh air for many.
Volgoat
I understand from your post the other day you are now holding a SHORT POS on PPHM unless this was a sarcastic post.